Analytical Data
-
Gene name
CDKN1B
- Application
-
Alternative Names
CDKN4; KIP1; P27KIP1; p27; Cyclin-dependent kinase inhibitor p27
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P46527
-
Expression Region
Met1~Thr198
-
Molecular Weight
30kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CDKN1B, also known as p27Kip1, is a crucial cell cycle regulator that functions as an inhibitor of cyclin-dependent kinases (CDKs). Its primary role is to maintain the balance between cell proliferation and differentiation, making it a key player in tumor suppression. Abnormal expression or mutation of CDKN1B has been linked to various cancers, including breast, prostate, and colon cancer, highlighting its significance in oncogenesis. The study of recombinant CDKN1B protein has gained momentum as it can serve as a valuable tool for understanding its molecular mechanisms and interactions with other cell cycle proteins. By producing this protein in a recombinant form, researchers can establish in vitro assays to unravel the complexities of its regulatory functions and identify potential therapeutic targets. Furthermore, recombinant CDKN1B can be utilized in drug screening assays to discover new anticancer compounds that aim to restore its normal function or enhance its activity. Recent advances in recombinant DNA technology have facilitated the production of CDKN1B at scale, allowing for extensive functional studies and the exploration of its roles in cellular signaling pathways, apoptosis, and proliferation. Such research endeavors not only enhance our understanding of cancer biology but also pave the way for innovative treatment strategies that could combat tumor growth by modulating the activity of this pivotal cell cycle regulator.
